Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Myriad Genetics Inc.
DescriptionDetects inherited mutations in the p16 gene (CDKN2A; INK4a)
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDetects inherited susceptibility to melanoma and pancreatic cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today